论文部分内容阅读
磷脂酰肌醇3-激酶(phosphatidylinositol 3-kinase,PI3K)/蛋白激酶B(protein kinase B,Akt)/哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,m TOR)信号通路是人体中的重要信号通路,通过逐级磷酸化下游蛋白发挥作用。非小细胞肺癌(non-small cell lung cancer,NSCLC)中存在该信号通路的异常活化。活化的信号通路可以改变NSCLC细胞的增殖、凋亡、侵袭和迁移等生物学特性从而影响其对治疗药物的反应及预后。针对该通路抑制剂的研究很多,部分抑制剂已进入临床研究阶段。PI3K抑制剂包括广谱PI3K抑制剂、亚型特异性的PI3K抑制剂和PI3K/m TOR双重抑制剂。PI3K抑制剂单药有效率较低,但与化疗药物或其他靶向药物联用取得了不错的临床效果,目前往往将PIK3CA突变以及抑癌基因PTEN的缺失作为预测疗效的指标,但准确性欠佳,进一步筛选疗效预测指标是目前面临的重要问题。
Phosphointidinositol 3-kinase (PI3K) / protein kinase B (Akt) / mammalian target of rapamycin (mTOR) signaling pathways are found in humans Important signaling pathways, which function by phosphorylating downstream proteins step by step. Abnormal activation of this signaling pathway exists in non-small cell lung cancer (NSCLC). Activation of the signal pathway can change the biological characteristics of NSCLC cells such as proliferation, apoptosis, invasion and migration and thus affect their response to treatment drugs and prognosis. Many studies have been made on this pathway inhibitor, and some inhibitors have entered the clinical research stage. PI3K inhibitors include a broad spectrum of PI3K inhibitors, subtype-specific PI3K inhibitors and PI3K / m TOR dual inhibitors. PI3K inhibitor single drug is less effective, but combined with chemotherapy drugs or other targeted drugs have achieved good clinical results, the current PIK3CA mutation and PTEN loss of tumor suppressor gene as an indicator of efficacy, but the accuracy of the lack of Good, further screening efficacy prediction index is currently facing an important issue.